Mylan and Biocon have secured the US Food and Drug Administration’s (FDA) approval for their fulphila, which is a biosimilar to neulasta.

Jointly developed by the companies, fulphila is indicated to minimise the febrile neutropenia duration in certain cancer patients undergoing chemotherapy. Symptoms of febrile neutropenia include a fever, other signs of infection and low neutrophil count.

Fulphila is the first biosimilar to neulasta approved by the FDA. The regulator’s decision comes after review of analytical, non-clinical and clinical data. The findings revealed that fulphila’s safety, purity and potency were mostly similar to neulasta.

Mylan president Rajiv Malik said: “Today’s approval of fulphila represents a meaningful step forward in the affordability and accessibility of cancer care in the US.

“It also is yet another confirmation of Mylan’s deep scientific, clinical, regulatory and intellectual property capabilities, which are widely recognised in the industry and bolster Mylan’s reputation as a partner of choice in the global effort to bring complex medicines to market.”

“This important milestone comes soon after our achievement of being the first to receive US FDA approval for biosimilar to herceptin.”

To be launched over the coming weeks, Fulphila is the second biosimilar in the partners’ joint portfolio to secure the FDA approval.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Their ogivri was approved in 2017 as a biosimilar to herceptin to treat HER2-overexpressing breast and metastatic stomach cancers.

Biocon CEO & joint managing director Dr. Arun Chandavarkar said: “This important milestone comes soon after our achievement of being the first to receive US FDA approval for biosimilar to herceptin.

“This approval expands our oncology portfolio for the benefit of cancer patients and supports our mission to improve access to high quality, affordable biopharmaceuticals globally.”